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Diacetylmorphine was first synthesised by C R Alder Wright in 1874 
as a highly potent, acetylated form of morphine. By 1898, Bayer 
pharmaceutical company marketed this drug under the trademark 
name of heroin. It was initially sold as a non-addictive morphine 
substitute and cough suppressant. However, heroin was soon found 
to be twice as powerful as morphine because it is highly fat soluble 
and rapidly crosses the blood-brain barrier. Despite subsequent strict 
controls imposed on the use of heroin, it remains the most widely 
used opiate.[1]
In 2009, there were an estimated 12 - 14 million heroin users 
worldwide.[1] Europe and Asia remain the key opiate consumption 
markets, but reports indicate that opiate use in Africa is increasing.[1] The 
2010 South African Community Epidemiology Network on Drug 
Use (SACENDU) statistics reveal that 5 - 20% of patients in specialist 
treatment centres in South Africa (SA) use heroin as their primary 
illicit drug of choice. In SA, heroin is primarily used by individuals 
aged 22 - 30 years,[2] and 20 - 40% of those treated for heroin abuse 
are female, which is a higher percentage than for most other illicit 
substances.
Opiate use is associated with menstrual irregularities, which 
combined with the often erratic lifestyles of drug-abusing women 
leads to a high rate of unplanned pregnancies. Heroin-dependent 
pregnant women represent an extremely vulnerable group of patients, 
who present with various medical, obstetric and psychiatric problems. 
There has been considerable debate about how best to manage these 
patients, as the needs of both fetus and mother require careful 
attention.
The ideal goal during pregnancy is for the mother to abstain from 
any drug use. When faced with a pregnant patient who is actively 
abusing heroin, one needs to offer treatment that will best minimise 
any further fetal and maternal harm. Given the highly addictive 
nature of opiates, it is difficult for many of these individuals to remain 
drug free, and some form of maintenance treatment is therefore 
usually offered.
An alternative to maintenance treatment is opioid withdrawal 
using methadone. Methadone detoxification involves using tapering 
doses of methadone to create a smooth transition from heroin use 
to a drug-free state. Withdrawal from methadone during pregnancy 
is not generally recommended in the literature,[3-5] except in specific 
situations such as when a motivated patient expresses a wish to 
withdraw from all opiates, or when methadone maintenance is 
unavailable – a state of affairs that is prevalent across all SA public 
treatment facilities.
Because pregnant women are rarely included in psychotropic 
clinical trials, relatively little information is available about the use 
of medication during pregnancy. The evidence-based management 
of pregnant patients who are dependent on opioids is therefore 
particularly challenging. While guidance is scarce, the prevailing 
opinion is that methadone maintenance is the gold standard of 
treatment in pregnancy.[3-5] This option is not available in SA state 
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facilities, where only methadone withdrawal is offered. It is therefore 
useful to review the data in the literature on the efficacy of methadone 
withdrawal in pregnancy.
Objectives
To conduct a systematic review of the literature on heroin detoxifica-
tion in pregnancy, and to report on pregnancy outcomes of heroin 
users who were detoxified with methadone at Groote Schuur Hospital 
(GSH), a teaching hospital in Cape Town, SA, during the 5-year 




The electronic databases PubMed, PsychINFO and the Cochrane 
Library were searched using a combination of the following search 
terms: pregnancy, heroin, opiate, methadone, buprenorphine, and 
treatment. Using the above terms, 14 English articles were located. 
Of these articles, 5 were relevant to the study. However, by using 
the article references, a total of 18 relevant articles were found and 
reviewed.
All relevant articles in English, reporting original data related to 
the treatment of heroin addiction in pregnancy, were included.
Using the above terms, 12 English articles were located on a 
PubMed search. Of these articles, 3 were relevant to the study. How-




GSH is a tertiary state hospital in Cape Town. The patients were 
managed in the labour ward or in C23, the emergency psychiatric 
ward.
Subjects
The study population included all pregnant heroin-addicted patients 
who underwent methadone detoxification at GSH between 2006 and 
2010, although the first recorded case was in 2008. The labour ward 
and C23 keep a register of all patients who have received methadone.
Methadone detoxification at GSH
A history of substance use is obtained from all patients admitted to 
maternity, bearing in mind that signs of heroin withdrawal appear 
within 8 hours after last dose and peak at 36 - 72 hours. GSH stocks 
equity methadone, which contains two milligrams of methadone per 
millilitre.
Following a positive history for heroin use, symptoms of heroin 
withdrawal are assessed. These symptoms are assessed using the 
Objective Opiate Withdrawal Scale (OOWS). This is a 13-item 
interview and observation tool that assesses for signs of heroin 
withdrawal.
In pregnant women, 5 mg/2.5 mL of oral methadone is admin-
istered if the OOWS score is 3 - 4. In women with an OOWS score of 
>4, 10 mg/5 mL methadone is given. The OOWS is repeated 2 hours 
later and further methadone administered as per the above scores. 
A maximum of 30 mg is administered; however, a doctor may give 
permission to give top-up doses in severe cases. Once the baseline 
dose has been established, a total dose of methadone can be given 
12-hourly. This is withdrawn slowly.
Further care depends on patient motivation and financial 
support. Patients who are not motivated to stop using heroin 
continue methadone during their hospital stay and are referred to 
a rehabilitation centre to continue motivational interviewing and 
psychosocial support. Patients who are motivated to stop using 
heroin can continue detoxification with support and follow-up. 
For patients who are financially able and willing, maintenance 
methadone is continued for the duration of the pregnancy.
Data collection
Pregnant patients treated during the study period were identified 
by means of information obtained from the methadone register. 
Both methadone registers were scrutinised carefully to ensure that 
all pregnant patients treated at GSH were identified. The outcomes 
of these pregnancies were then determined by looking at specific 
maternal and fetal parameters as listed in the ‘Prospective case series’, 
‘Literature reviews’ and ‘Case studies’ sections of Table 1.
Ethical considerations
The study was approved by the University of Cape Town Human 
Research Ethics Committee (ref. no. 072/2010), and permission 
was granted to access information from the clinical files. Only 
information relevant to the study was extracted from the patient files, 
and all the identifying data were kept confidential.
Results
Systematic review
A total of 20 relevant articles were found, which were reported 
in 15 publi cations. The majority were prospective case series, but 
others included retrospective case series, case reports, literature 
reviews and descriptive studies (Table 1).
Heroin is not considered to be grossly teratogenic, but it is 
highly lipophilic and readily crosses the placenta. Untreated heroin 
use is associated with intrauterine growth restriction, premature 
delivery, increased neonatal mortality and neonatal abstinence 
syndrome (NAS), which is characterised by a variety of signs and 
symptoms in the neonate that indicate dysfunction of the autonomic 
nervous system, gastrointestinal tract and respiratory system. There 
is therefore a need for any kind of intervention that will reduce 
or eliminate maternal heroin use in order to improve pregnancy 
outcomes.
Maas et al.[8] published an intervention study in 1990 that 
compared the pregnancy outcomes of mothers joining a methadone 
detoxification programme with those of mothers who continued 
uncontrolled street-drug use. They found that 17 out of 58 women 
successfully completed heroin detoxification during the antenatal 
period. The incidence of neonatal abstinence syndrome was reduced 
after maternal participation in the detoxification programme – 55% 
v. 88%. Newborns of mothers who had successfully detoxified 
experienced fewer withdrawal symptoms, and no adverse obstetric 
complications were reported in this group.
According to most widely accepted recommendations, withdrawal 
of methadone is not advised before 14 weeks’ gestation because of 
the potential risk of inducing abortion, and should not be performed 
after the 32nd week of pregnancy because of possible withdrawal-
induced stress.[4,5] This view is largely the result of two influential 
case reports published in the 1970s. Rementeria and Nunag[5] 
described a stillbirth at term following acute methadone withdrawal, 
and Zuspan et al.[18] described a case of increased amniotic fluid 
epinephrine levels during methadone withdrawal, which resolved 
once the methadone dose was increased.
These initial concerns have since been challenged. In a retro-
spective study in 2003, Luty et al.[20] reviewed 101 case reports of 
methadone withdrawal conducted at various stages of pregnancy. 
They concluded that detoxification treatment was not associated with 
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Table 1. Summary of systematic review
Title Authors Journal and year Summary
Literature review and prospective case series
 Adverse neurodevelopmental 
outcome of infants exposed to 
opiate in utero
Hunt et al.[6] Early Human 
Development, 2008
Review of the literature examining neurodevelopmental 
outcome in infants with NAS. 33 opiate-exposed 
infants who were identified after development of NAS 
compared with controls. Opiate-exposed infants showed 
neurodevelopmental impairment and reduced growth.
Prospective case series
 Maternal narcotic abuse and the 
newborn
Alroomi et al.[7] Archives of Disease in 
Childhood, 1988
Opiate-exposed infants have higher rates of NAS, 
preterm delivery, IUGR and neonatal mortality.
 Infrequent neonatal opiate 
withdrawal following maternal 
methadone detoxification during 
pregnancy
Maas et al.[8] Journal of Perinatal 
Medicine, 1990
Influence of maternal participation in a methadone 
detox programme was compared with street drug use on 
neonatal morbidity in 75 neonates. NAS occurred in 63% 
of neonates, and was less frequent after methadone detox.
 Opioid detoxification in 
pregnancy
Dashe et al.[9] Obstetrics and 
Gynaecology, 1998 
34 pregnant opiate-dependent women offered methadone 
detoxification. 59% were successfully detoxified with 
no adverse pregnancy outcomes, or relapse to illicit 
substances.
 Methadone maintenance 
programme in a Swiss perinatal 
centre: Management and outcome 
of 89 pregnancies
Kashiwagi et al.[10] Acta Obstetricia 
et Gynecologica 
Scandinavica, 2005
84 pregnant opiate-dependent women offered methadone 
maintenance. 11 attempted detoxification, but ~50% 
returned to maintenance therapy. 64% continued to use 
illicit substances while in programme.
 Methadone maintenance 
v. methadone taper during 
pregnancy: Maternal and neonatal 
outcomes
Jones et al.[11] American Journal on 
Addictions, 2008
175 opioid-dependent pregnant women given methadone 
maintenance, methadone withdrawal alone, or 
withdrawal followed by maintenance. Given the poor 
maternal outcomes with withdrawal alone, maintenance 
should be considered as the primary treatment approach.
 The cost of crime and the benefits 
of substance abuse treatment for 
pregnant women
Daley et al.[12] Journal of Substance 
Abuse Treatment, 
2000
Differences in criminal activity were measured in 439 
pregnant women entering five different treatment 
programmes. The reduction in crime-related costs was 
greatest in residential substance abuse facilities. The cost 
of the treatment facility was more than covered by the 
cost-saving in crime reduction.
 Improving treatment outcome 
in pregnant opiate-dependent 
women. 
Chang et al.[13] Journal of Substance 
Abuse Treatment, 
1992
Outcomes of 6 pregnant methadone-maintained opiate-
dependent women in an enhanced programme were 
compared with those of 6 women receiving conventional 
methadone maintenance. The enhanced-programme 
participants had better pregnancy outcomes than the 
controls.
 Management of pregnant drug-
dependent women
Finnegan[14] Annals of the New 
York Academy of 
Sciences, 1978
The pregnancy outcomes of 367 opiate-dependent 
women were compared with 215 non-drug-dependent 
women. The groups were further divided into those 
receiving an enhanced prenatal programme v. standard 
care. Infant mortality was reduced in the opiate-
dependent group in the enhanced programme.
 Prospective multicentre 
observational study of 260 infants 
born to 259 opiate-dependent 
mothers on methadone or high-
dose buprenophine substitution
Lejeune et al.[15] Drug and Alcohol 
Dependence, 2006
Substitution with methadone or buprenorphine improves 
pregnancy outcomes.
Literature reviews
 Methadone treatment during 
pregnancy




Methadone treatment is only beneficial if administered as 
part of a comprehensive care package.
 Treating pregnant women 
dependent on opioids is not the 
same as treating pregnancy and 
opioid dependence
Winklbaur et al.[17] Addiction, 2008 Use of opioid medication for detox or maintenance 
should follow established national guidelines, but should 
be done in a co-ordinated and supportive environment. 
Continued ...
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any risk of miscarriage in the second trimester or with premature 
delivery in the third trimester. Similarly, Dashe et al.[9] conducted a 
prospective study in which 35 opioid-addicted pregnant patients were 
offered inpatient opiate detoxification with methadone; 59% of them 
successfully completed heroin detoxification, did not relapse, and had 
no adverse pregnancy outcomes.
Apart from the risk of fetal harm during methadone detoxification, 
the major concern with not providing long-term methadone 
treatment is an increased risk of relapse to illicit drug use. There is 
a perception that mothers engaged in maintenance programmes are 
less likely than those who are not to use illicit drugs, or to engage in 
other drug-seeking behaviours such as prostitution.
Wong et al.[3] conducted a literature review of substance abuse in 
pregnancy in order to provide recommendations on management. 
They concluded that methadone maintenance treatment is associated 
with longer adherence to treatment and a decreased risk of relapse 
to opioid use, and therefore proposed that the preferred standard of 
care for pregnant opioid-dependent women is substitution therapy.
However, some studies have shown that methadone maintenance 
treatment does not guarantee abstinence. Kashiwagi et al.[10] explored 
pregnancy outcomes among women in a major Swiss methadone 
maintenance programme, and 64% of the women were found to be 
co-users of cocaine and/or heroin.
Apart from not always curtailing illicit drug use, management 
with methadone poses its own risks. Fetal methadone dependence 
has been associated with fetal death, growth restriction, preterm 
birth, meconium aspiration and NAS.[7] It has been estimated that 
60 - 87% of neonates born to methadone-maintained mothers require 
treatment for NAS. Neonates suffering from NAS grow poorly in the 
neonatal period, and have reduced height compared with controls at 
3 years of age.[12]
The longer-term implications of methadone maintenance treatment 
are also not clear. Hunt et al.[6] conducted a study on infants who had 
developed NAS, and found that they had evidence of both cognitive 
and psychomotor deficit on psychometric testing compared with 
non-opiate-exposed controls. Recent literature has also reported an 
increased incidence of ocular abnormalities in infants of methadone-
maintained mothers. The possibility of long-term visual and cortical 
defects is alarming, and requires further research.
Methadone withdrawal is the standard management of pregnant 
heroin addicts in state hospitals in SA. This is largely due to financial 
constraints, as methadone maintenance management is more costly 
Table 1. (continued) Summary of systematic review
Title Authors Journal and year Summary
Case studies
 Narcotic withdrawal in 
pregnancy: Stillbirth incidence 




of Obstetrics and 
Gynecology, 1973
Description of one patient who had a stillbirth following 
third-trimester methadone withdrawal. The authors 
therefore caution against methadone withdrawal in the 
third trimester.
 Fetal stress from methadone 
withdrawal
Zuspan et al.[18] American Journal 
of Obstetrics and 
Gynecology, 1975
Description of one patient who developed increased 
amniotic fluid epinephrine levels while undergoing 
methadone withdrawal. The authors recommend 
avoiding detoxification.
 Detoxification with 
buprenorphine of a pregnant 
heroin addict
Annitto[19] American Journal on 
Addictions, 2000
Description of a patient withdrawn successfully 
using buprenorphine. The author cautions that more 
information is needed regarding buprenorphine 
withdrawal.
Retrospective case series
 Is opiate detoxification unsafe in 
pregnancy?
Luty et al.[20] Journal of Substance 
Abuse Treatment, 
2003
101 pregnant opiate-dependent women underwent 
detoxification at various pregnancy stages. Methadone 
detox was not associated with adverse effects in the 
second or third trimester.
 Methadone maintenance in 
pregnancy: Consequences to care 
and outcomes
Edelin et al.[21] Obstetrics and 
Gynaecology, 1989
Pregnancy outcomes of 26 narcotic-addicted women 
enrolled in a methadone maintenance programme 
compared with 37 polydrug users not in the programme. 
No major difference in outcomes found between the two 
groups.
Descriptive studies
 Detoxification considerations 
in the medical management of 
substance abuse in pregnancy
Allen[22] Bulletin of the New 
York Academy of 
Medicine, 1991
Methadone maintenance has become the mode of 
therapy for most patients based on early case reports.
 The management of heroin 
misuse in pregnancy: Time for a 
rethink? 
Mactier[23] Archives of Disease in 
Childhood, Fetal and 
Neonatal Edition, 
2011
There is increasing evidence of adverse effects upon 
developing cortical and visual function in children of 
treated heroin-addicted mothers. Studies are needed that 
take into account longer-term outcomes for the child.
Systematic review
Substance use in pregnancy Wong et al.[3] Journal of Obstetrics 
and Gynaecology 
Canada, 2011
Review of the literature of substance abuse in pregnancy. 
Methadone maintenance recommended owing to 
reduced relapse to illicit substances.
NAS = neonatal abstinence syndrome; IUGR = intrauterine growth retardation.
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than withdrawal. This concept has, however, been challenged by 
Daley et al.,[12] who suggest that the healthcare costs should not be 
viewed in isolation. They argue that maintenance treatment reduces 
maternal criminal behaviour by reducing illicit drug use, which has 
secondary cost implications for society. The authors conducted a 
study in Massachusetts, USA, which indicated that the cost of crime 
far outweighed that of substance abuse treatment.
It seems that medical professionals need to shift the focus of 
attention from the medical management of cravings and fluctuating 
maternal opiate levels to providing a more comprehensive care 
package. Studies conducted by Chang et al.[13] and Finnegan[14] found 
that methadone maintenance, in addition to intensive antenatal care, 
is compatible with an uneventful pregnancy and birth of a healthy 
infant.
The GSH study
Because methadone is a highly addictive schedule 6 drug, its 
administration is recorded in a methadone register. This register 
shows that only six pregnant heroin-addicted patients received 
methadone detoxification at GSH between 2006 and 2010, although 
the first case recorded was in 2008. The clinical details of these 
patients are shown in Tables 2 - 4.
A total of six pregnant patients received methadone withdrawal at 
GSH between 2008 and 2010. Their ages ranged from 17 to 37 years. 
Four of the six patients were single and one was divorced, and half 
of them were of high parity. Apart from patient D, all the patients 
booked late (defined as booking after 20 weeks’ gestation). All the 
patients were HIV-negative, and none had current syphilis infection.
Surprisingly, none of the patients abused alcohol, and patients 
B and F were the only two patients who used other substances – 
benzodiazepines and methamphetamine, respectively. All six patients 
underwent detoxification at some point during their pregnancies, 
with patients A and B requiring detoxification prior to delivery. There 
was no record of any psychiatric follow-up for any of the patients 
after detoxification, apart from patient D, who could afford a private 
rehabilitation facility.
Four of the patients delivered at term, patient B delivered at 33 
weeks’ gestation following heroin detoxification with methadone, and 
patient F delivered spontaneously 1 week short of term. Half of the 
patients required caesarean section. Patient A required an emergency 
caesarean section for fetal distress due to placental abruption; 
however, it was not clear from the records if this was due to her 
ongoing heroin use or another obstetric cause. Interestingly, all the 
neonates had Apgar scores ranging from 7 to 10, and none of them 
required resuscitation. None of the neonates showed signs of NAS. 
All the patients were discharged from the maternity ward within 
3 days after delivery.
Discussion
After review of the various studies found in the literature, it is apparent 
that data on the safety and efficacy of methadone detoxification 
are limited. There are, however, good data on the need to develop 
comprehensive treatment programmes that go beyond the dispensing 
of methadone and/or other medication. Pregnancy is often described 
as a useful period for encouraging behavioural changes. However, 
methadone alone, whether given as detoxification or maintenance, does 
not correct underlying psychosocial problems or address behaviour 
changes. The best outcomes are most likely to be reached by using an 
integrated care plan incorporating pharmacological, psychotherapeutic 
and social interventions. The most striking feature of our case series 
is the relatively low number of patients who received methadone 
detoxification, despite the rising rates of heroin use and the burden of 
disease encountered in Cape Town.
Given that the 2010 SACENDU statistics reveal that heroin is the 
primary substance of abuse among 13% of substance abusers in the 
Western Cape Province,[2] it may be speculated that heroin-addicted 
pregnant patients are inadequately screened for, or are offered 
detoxification with only benzodiazepines and analgesics. There are 
two possible explanations for this. Firstly, these patients may face 
tremendous stigma, not only from their families and society but 
also from healthcare providers, and they may therefore be treated 
with little sympathy, being perceived as attempting to manipulate 
the system by requesting methadone treatment. Secondly, healthcare 
workers may be concerned about the risk of exposing the fetus to 
another potentially harmful substance.
Five of the six patients had received methadone detoxification 
prior to delivery, while patient B went into labour during her 
withdrawal. Of the five patients who completed their detoxification, 
three resumed using heroin prior to their delivery, with patient A 
requiring a second detoxification at the time of delivery. In this small 
sample, the relapse rate is low given the fact that only one patient 
received continued psychosocial support after discharge. This low 
Table 2. Maternal demographic data
Patient
A B C D E F
Age, years 24 37 21 34 17 28
Marital status Divorced Single Single Single Single Married
Gestation, weeks 37+ 33 42+ 39 38+ 36
Obstetric history G5P2M1SB1 G1P0 G1P0 G5P1M2T1 G1P0 G4P3












Booking, weeks 29 32 31 11 24 33
Antenatal
Visits, n 8 2 4 5 4 1
Complications No Admitted No No No No
Nicotine use Yes Yes No No Yes Yes
Alcohol use No No No No No No
Other substance use Heroin Heroin
Benzodiazepines
Heroin Heroin Heroin Heroin
Meth 
G = gravida; P = para; M = miscarriage; SB = stillbirth; T = termination; Meth = methamphetamine.
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rate of relapse indicates that methadone detoxification may be a 
successful way of managing these patients. One of the main criticisms 
of withdrawal treatment is the high rate of relapse to heroin use, 
which was shown not to be the case in this small population. This 
having been said, a relapse rate of 60% is not negligible, and ideally, 
further psychosocial measures should be implemented to assist in 
maintaining abstinence.
A major concern with methadone maintenance treatment is the 
high risk of NAS. This syndrome is characterised by central nervous 
system excitability in newborn infants, and in many cases requires 
pharmacological withdrawal treatment. All the infants of the six 
patients described were born without showing any sign of opioid 
withdrawal, had good Apgar scores and required no resuscitation. 
As mentioned earlier, the literature suggests that NAS requiring 
Table 4. Neonatal data
Patient
A B C D E F
Delivery
Mode CS Vacuum CS CS NVD NVD
Indication AP, FDS Spontaneous 
labour
FDS Previous CS Pre-labour ROM Spontaneous 
labour
Date 4 Nov 2009 10 Jun 2008 25 May 2010 16 Jun 2010 Pre-labour ROM on 
11 Aug 2010, given 
oxytocin
NVD 13 Aug 2010
23 Mar 2010
Apgar score
1 min 8/10 7/10 9/10 9/10 8/10 9/10
5 min 10/10 9/10 10/10 10/10 10/10 9/10
Sex of neonate F M M F M F
Measurements
Birth weight, g 2 200 2 110 3 960 2 600 3 540 3 240
Head circumference, cm 33 34 36 31 33 34
Resuscitation No No No No No No
NAS No No No No No No
Discharge
Date 7 Nov 13 Jun 28 May 19 Jun 14 Aug 24 Mar
Treatment Referred to C23, 
self-discharge 
against advice
Diazepam No meds No meds No meds No meds
CS = caesarean section; NVD = normal vertex delivery; AP = abruptio placentae; FDS = fetal distress syndrome; ROM = rupture of membranes; F = female; M = male; 
NAS = neonatal abstinence syndrome; C23 = emergency psychiatric ward. 
Table 3. Heroin use and methadone withdrawal
Patient
A B C D E F
Antenatal management of 
heroin use
Admission (for detox) Yes Yes Yes Yes Yes Yes
Place STH GSH GSH GSH GSH GSH
Duration 30 Jun - 7 Sep 2009 5 Jun 2008 9 - 11 Mar 2010 21 - 23 Apr 
2010
15 - 21 Jul 2010 9 - 11 Mar 
2010
After detox No known follow-up Labour and 
delivery




 Ongoing use of heroin 
post detox
Yes No Yes No Yes No
Admission date to maternity 
wards and reason
27 Oct for detox 5 Jun for detox 24 May in 
labour




11 Aug with 
pre-labour 
ROM
23 Mar in 
labour
Date of last heroin use 27 Oct 4 Jun 22 May 21 Apr 28 Jul 9 Mar
Methadone use during 
admission to maternity
28 - 30 Oct: 10 mL/20 mg
31 Oct - 1 Nov: 8 mL/16 mg
2 - 3 Nov: 6 mL/12 mg
9 - 11 Jun: 
8 mL/16 mg
None None None None
STH = Stikland Hospital; GSH = Groote Schuur Hospital; CTDC = Cape Town Drug Counselling Centre; ROM = rupture of membranes.
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treatment occurs in at least two-thirds of infants born to mothers 
on methadone maintenance. The positive neonatal outcome in this 
group is therefore significant, as it highlights a major advantage of 
methadone detoxification over maintenance.
Rementeria and Nunag[5] cautioned against detoxification after 
32 weeks’ gestation owing to concerns about precipitating early 
delivery. Four of the six patients (A, B, E and F) were detoxified 
after 32 weeks, with patient A requiring a second detoxification at 
term, and two of the four (A and B) went into labour during the 
detoxification process, patient B having premature delivery at 33 weeks. 
These findings support the view that detoxification is safest during 
the second trimester.
An interesting finding in these six patients was the low rate of 
comorbid substance abuse, and the fact that none of them were 
infected with HIV or with syphilis. This group of patients is usually 
at high risk for polysubstance abuse and sexually transmitted 
infections. The absence of these common additional problems may 
also partly explain the relatively good neonatal outcomes in the 
group.
The apparent discrepancy in the resources available to heroin-
addicted pregnant women in developed countries compared with 
SA is disheartening. The focus of most research has shifted 
from determining the merits of maintenance v. withdrawal 
to determining which medication is superior in maintenance 
management. SA state facilities continue to offer only methadone 
as substitution medication, and only for a limited period while 
undergoing withdrawal. This management of heroin withdrawal 
by detoxification and lack of opiate substitution treatment in 
government facilities in SA highlights the need for a greater focus 
on pharmacological harm reduction strategies in low- and middle-
income countries.
Study limitations
The limitations of the current data set include the small sample size, 
the retrospective ratings, and the lack of any follow-up information. 
Despite this, however, these data suggest that favourable outcomes 
of pregnancies managed with methadone withdrawal are possible. 
Additional research is nevertheless required to confirm these 
preliminary findings.
Conclusions
There is limited evidence on the management of heroin addiction 
during pregnancy, and the only two guidelines identified suggest 
that methadone maintenance is preferable to methadone withdrawal. 
The favourable pregnancy outcomes in this small sample of patients 
managed with methadone withdrawal suggest that it may be safe and 
deserves further study.
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